THE EFFECTS OF 'PROFETAL' PREPARATION UPON FUNCTIONAL ACTIVITY OF HUMAN MONONUCLEAR LEUKOCYTES AND DENDRITIC CELLS

Abstract. The effects of 'Profetal', a drug containing liophylized, dextran-stabilized human alpha-fetoprotein as main active component, were investigated on peripheral donor blood mononuclear leukocytes (ML), with respect to their functional properties and the potential to generate mature dendritic cells (DC).

Addition of the drug to cell cultures at optimal doses was shown to cause significant increase in their proliferative capacity and ML blastic transformation levels, and enhanced cytotoxicity towards K562 tumor cells, as well as to induce maturation of antigen-presenting dendritic cells.

On the basis of the data obtained, a conclusion is made that 'Profetal' is an active immunomodulatory factor, and it may be applied for generation of cytotoxic lymphocytes and mature DC, aiming to apply them for the biotherapy of oncological and infectious diseases.

1. Барышников А.Ю. Взаимоотношение опухоли и иммунной системы организма // Практическая онкология. — 2003. — Т. 4. — №3. — С. 127–129.

2. Киселевский М.В., Титов К.С., Тер–Ованесов М.Д. Перспективы адоптивной иммунотерапии радикально оперированного рака желудка // Российский биотерапевтический журнал. — 2002. — №4. — С. 46–48.

3. Кузнецова А.В., Данилова Т.И., Гладских О.П., Иванов А.А., Пальцев М.А. Дендритные клетки и их использование в иммунотерапии // Молекулярная медицина. — 2003. — №3. — С. 3–17.

4. Лилли Р. Патогистологическая техника и практическая гистохимия / М.: Мир, 1969. — С. 128–131.

5. Пальцев М.А. Введение в молекулярную медицину / Под редакцией Пальцева М.А. — М.: ОАО Издво «Медицина», 2004. — 496 с.

6. Пащенков М.В., Пинегин Б.В. Основные свойства дендритных клеток // Иммунология. — 2001. — №3. — С. 7–16.

7. Родина А.В., Москалева Е.Ю., Беляев Д.Л. Получение функционально активных дендритных клеток человека с использованием препарата лейкинферон в качестве индуктора созревания // Аллергия, астма и клиническая иммунология. — 2003. — Т. 7. — № 9. — С. 19–27.

8. Черешнев В.А., Родионов С.Ю., Черкасов В.А., Малютина Н.Н., Орлов О.А. / Альфа–фетопротеин. — Екатеринбург: УрО РАН, 2004. — 376 с.

9. Чикилева И.О., Халтурина Е.О., Киселевский М.В. Современные подходы и направления в иммунотерапии и иммунопрофилактике злокачественных новообразований // Молекулярная медицина. — 2003. — №2. — С. 40–50.

10. Ardavin С, Martinez del Hoyo G., Martin P. Origin and differentiation of dendritic cells // Trends in Immunology. — 2001. — V. 22. — P. 691–700.

11. Banchereau J., Steinman R. M. Dendritic cells and the control of immunity // Nature. — 1998. — V. 392. — P. 245–252.

12. Blymenberg A.G., Kiselevski M.V., Gorbunova V.A., Volkov S.V., Kadagidze Z.G. Immunotherapy IL2/LAK for the treatment of platinum and taxman–resistant advanced // International journal of gynecological cancer. — 2002. — V. 12. — N. 5. — P. 70.

13. Carlens S., Gilljam M., Chambers B.J., Aschan J., Guven H., Ljunggren H.G., Christensson B., Dilber M.S. A new method for in vitro expansion of cytotoxic human CD3–CD56+ natural killer cells // Hum. Immunol. — 2001. — V. 62. — P. 1092–1098.

14. Chen Z., Dehm S., Bonham K. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy // Cell Immunol.2001. — V. 214. — P. 60–71.

15. Cho B.K. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins // Immunity. — 2000. — V. 12. — P. 263–272.

16. Dhodapkar M.V. Active immunization of humans with dendritic cells // J. Clin. Immunol. — 2000. — V. 20. — P. 167–173.

17. Dudich E.I., Semenkova L.N., Dudich I.V. et al. Alpha–fetoprotein–induced apoptosis of cancer cells // Bull. Biol. Med. — 2000. — V. 130. — №12. — P. 1127–1133.

18. Enk A.H. & Jonuleit H. How do dendritic cells prevent autoimmunity: what is a mature dendritic cell in the mouse? // Trends in Immunology. — 2001. — V. 22. — P. 547–553.

19. Falk C.S., Noessner E., Weiss E.H., Schendel D.J. Retaliation against tumor cells shoing aberrnt HLA expression using lymphokine activated killer–derived T cells // Cancer Res. — 2002. — V. 62. — P. 480–487.

20. Ferlazzo G., Wesa A., Wei W.Z. Dendritic cells generated from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen–specific CD8+ T cells // J. Immunol. — 1999. — V. 163. — P. 35–97.

21. Granucci F., Andrews D.M., Degli–Espoti M.A. IL–2 mediates adjuvant effect of dendritic cells // Trends in Immunology. — 2002. — V. 23. — P. 169–171.

22. Heufler C., Koch F., Stanzl U. Interleukin–12 is produced by dendritic cells and mediates T helper 1 developments as well as interferon–gamma production by T helper 1 cells // J. Immunol. — 1996. — V. 26. — P. 659–668.

23. Jefford M., Maraskovsky E., Cebon J., Davis I. D. The use of dendritic cells in cancer therapy // Lancet Oncol. — 2001. — V. 2. — P. 343–353.

24. Keller R. Dendritic cells: their significance in health and disease // Immunol. Letters.– 2001. — V. 78. — P. 113–122.

25. Lotze M.T. Thomson A.W. Dendritic cells. Biology and clinical applications / N–Y.: Academic Press. — 1999. — P. 214–237.

26. Nishiyama T., Tachibana M., Horiguchi Y. Immunotherapy of bladder using autologous dendritic cells pulsed with human lymphocyte antigen–A24–specific MAGE–3 peptide // Clin. Cancer. Res. — 2001. — V. 7. — P. 23–31.

27. Nouri–Shirazi M., Banchereau J., Fay J. Dendritic cell based tumor vaccines // Immunol. Letters. — 2000. — V. 74. — P. 5–10.

28. Reid C.D.L. Dendritic cells and immunotherapy for malignant disease / C.D.L. Reid // British J. Haematol .– 2001. — V. 112. — P. 874–887.

29. Thurner B., Haendle I., Roder C. Vaccination with MAGE–3 A1 peptide–pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma // J. Exp. Med. — 1999. — V. 190. — P. 1669–1678.

30. Valone F.H., Small E., MacKezie M. Dendritic cell–based treatment of cancer: closing in on a cellular therapy // Cancer J. — 2001. — V. 7. — P. 53–61.